LYON, France--(BUSINESS WIRE)--Dec. 21, 2005--Flamel Technologies (NASDAQ:FLML) announced today that its collaborator, GlaxoSmithKline, has submitted a New Drug Application (NDA) for the controlled release formulation of a currently marketed major GSK drug using Flamel’s Micropump(R) technology. The filing by GSK will result in the payment of a $2 million milestone under a license agreement between the companies, which was entered into in March of 2003. “The submission of this NDA is an important milestone for Flamel Technologies,” said Stephen H. Willard, Flamel’s chief executive officer. “I believe it is a significant validation of Flamel’s Micropump technology platform, as well as confirmation of Flamel’s ability to deliver practical success in providing drug delivery solutions from formulation to NDA filing.”
